A US policy perspective on oral preexposure prophylaxis for HIV

American Journal of Public Health

Volumn 101, Issue 6, 2011, Pages 982-985

  Leibowitz, Arleen A ^a   Parker, Karen Byrnes ^a   Rotheram Borus, Mary Jane ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ARTICLE; BIOETHICS; COUNSELING; ECONOMICS; HEALTH CARE PLANNING; HEALTH CARE POLICY; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); UNITED STATES;

ADMINISTRATION, ORAL; ANTI-HIV AGENTS; BIOETHICAL ISSUES; COUNSELING; HEALTH POLICY; HEALTH RESOURCES; HIV INFECTIONS; HOMOSEXUALITY, MALE; HUMANS; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; UNITED STATES;

EID: 79956365524     PISSN: 00900036     EISSN: 15410048     Source Type: Journal    
DOI: 10.2105/AJPH.2010.300066     Document Type: Review

References (26)

1. Garcia-Lerma JG, Paxton L, Kilmarx PH, Heneine W. Oral pre-exposure prophylaxis for HIV prevention. Trends Pharmacol Sci. 2010;31(2):74-81.
2. AIDS Vaccine Advocacy Coalition. Ongoing PrEP trials, PrEP trials map. Available at: http://www.avac.org/ht/d/sp/i/3507/pid/3507d/sp/i/3507/pid/3507. Accessed June 3, 2010.
3. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587- 2599.
4. Kim SC, Becker S, Diffenbach C, et al. Planning for pre-exposure prophylaxis to prevent HIV transmission: challenges and opportunities. J Int AIDS Soc. 2010;13:24.
5. AIDS Vaccine Advocacy Coalition. Summary from the AVAC Think Tank on PrEP financing in the US. Available at: http://www.avac.org/ht/d/sp/a/ GetDocumentAction/i/3529. Accessed June 3, 2010.
6. Paxton LA, Hope T, Jaffe HW. Preexposure prophylaxis for HIV-infection: what if it works? Lancet. 2007;370(9581):89-93. (Pubitemid 47033881)
7. Liu AY, Grant RM, Buchbinder SP. Prexposure prophylasis for HIV: unproven promise and potential pitfalls. JAMA. 2006;296(7):863-865. (Pubitemid 44223110)
8. Centers for Disease Control and Prevention. Pre-exposure prophylaxis (PrEP) for HIV prevention: planning for potential implementation in the U. S. August 1, 2009. Available at: http://www.cdc.gov/hiv/prep/resources/factsheets/ implementation.htm. Accessed on June 9, 2010.
9. Institute of Medicine Committee on HIV Screening and Access to Care. HIV Screening and Access to Care: Exploring Barriers and Facilitators to Expanded HIV Testing. Washington, DC: The National Academies Press; 2010.
10. Center for HIV Identification, Prevention and Treatment. Preparing for PrEP: A Stakeholder's Dialogue. Conference Proceedings. Available at: http://chipts. ucla.edu/ReportsAndPublications/index.asp. Accessed June 9, 2010.
11. National Alliance of State and Territorial AIDS Directors. Support FY2010 HIV prevention funding. Available at: http://www.nastad.org/Docs/Public/ Resource/2009526-FY2010%20 CDC%20HIV%20Prevention.pdf. Accessed June 9, 2010.
12. Guest G, Shattuck D, Johnson L, et al. Changes in sexual risk behavior among participants in a PrEP HIV prevention trial. Sex Transm Dis. 2008;35(12):1002-1008.
13. Grant RM. Reflection on retention. Global iPrEX update number 4. Available at: http://www.globaliprex.com/pdfs/iPrEx-Update-4-pages.pdf. Accessed June 9, 2010.
14. Supervie V, Garcia-Lerma JG, Heneine W, et al. HIV, transmitted drug resistance, and the paradox of preexposure prophylaxis. Proc Natl Acad Sci U S A. 2010;107(27):12381-12386.
15. Crepaz N, Marks G, Liau A, et al. Prevalence of unprotected anal intercourse among HIV-diagnosed MSM in the United States: a meta-analysis. AIDS. 2009;23(13):1617-1629.
16. Berg RC. Barebacking: a review of the literatures. Arch Sex Behav. 2009;38(5):754-764.
17. Golub SA, Kowalczyk W, Weinberger CL, Parsons JT. Preexposure prophylaxis and predicted condom use among high-risk men who have sex with men. J Acquir Immune Defic Syndr. 2010;54(5):548-555.
18. Grant RM. A pill a day to keep HIV away. Presentation at: the Los Angeles Prevention Planning Council; January 6, 2011.
19. Desai K, Sansom SL, Ackers ML, et al. Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the United States: HIV infections prevented and cost-effectiveness. AIDS. 2008;22(14):1829-1839.
20. Paltiel AD, Freedberg KA, Scot CA, et al. HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and costeffectiveness. Clin Infect Dis. 2009;48(6):806-815.
21. Das M, Chu PL, Santos GM, et al. Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS ONE. 2010;5(6): e11068.
22. Paltiel AD, Walensky RP, Schakman BR, et al. Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs. Ann Intern Med. 2006;145(11):797-806. (Pubitemid 351650333)
23. Pinkerton SD, Martin JN, Roland ME, Katz MH, Coates TJ, Kahn JO. Cost-effectiveness of postexposure prophylaxis after sexual or injection drug exposure to human immunodeficiency virus. Arch Intern Med. 2004;164(1):46-54. (Pubitemid 38067388)
24. Shoptaw S, Rotheram-Fuller E, Landovitz RJ, et al. Non-occupational post-exposure prohpylaxis as a biobehavioral HIV prevention intervention. AIDS Care. 2008;20(3):376-381. (Pubitemid 351451243)
25. Hornberger J, Holodniy M, Robertus K, et al. A systematic review of cost-utility analyses in HIV/AIDS: implications for public policy. Med Decis Making. 2007;27(6):789-821. (Pubitemid 350136010)
26. National Alliance of State and Territorial AIDS Directors. The ADAP Watch, February 11, 2011. Available at: http://nastad.org/InFocus/InfocusResults Details.aspx?infocus-id=355. Accessed February 14, 2011.